Bristol-Myers Squibb Company BMY reported better-than-expected results for the second quarter of 2020 as blood thinner drug, Eliquis, and addition of sales from Celgene’s drugs (acquired in November 2019) maintained momentum. The company lifted its earnings guidance for 2020 in hope of a possible recovery in the second half of 2020.
Shares were up in pre-market trading following the earnings release. Bristol-Myers’ shares have lost 7% in the year so far against the industry's growth of 5.7%.
Second-quarter 2020 earnings of $1.63 per share easily beat the Zacks Consensus Estimate of $1.46 and increased from the year-ago quarter’s $1.18.
Total revenues of $10.12 billion beat the Zacks Consensus Estimate of $10.1 billion and surged 61% from $6.3 billion in the year-ago period. Strong growth was mainly driven by the addition of Celgene’s products.
On a pro-forma basis, revenues were consistent as sales were negatively impacted by approximately $600 million mainly due to COVID-19-related channel inventory work downs from the first quarter as well as lower demand resulting from reduced new patient starts and fewer patient visits to physicians during the pandemic.
Revenues increased 77% to $6.5 billion in the United States and 40% outside the country. Ex-U.S. revenues were up 43% when adjusted for foreign exchange impact.
Eliquis witnessed strong growth, rising 6% to $2.2 billion. We note that Bristol-Myers has a collaboration agreement with Pfizer PFE for Eliquis. However, sales of Opdivo, which is approved for multiple cancer indications, declined 9% year over year to $1.65 billion.
Leukemia drug, Sprycel, raked in sales of $511 million, down 6% year over year. Sales of rheumatoid arthritis drug, Orencia, were down 4% to $750 million. Melanoma drug, Yervoy, contributed $369 million to the top line, up 1% year over year.
Multiple myeloma drug, Empliciti, recorded sales of $97 million, up 7% year over year.
The performance of key drugs in the Virology unit was disappointing. Sales of Baraclude declined 18% to $121 million. Sales of other brands (including Sustiva, Reyataz, Daklinza and all other products that have lost exclusivity in major markets) fell 31% year over year to $331 million.
Myeloma drug, Revlimid, added with Celgene’s acquisition, contributed $2.9 billion to the top line and was the top-revenue generator for Bristol-Myers. Other key drugs from Celgene — Pomalyst and Abraxane — generated sales of $745 million and $308 million, respectively.
Adjusted research and development (R&D) expenses in the quarter increased to $2.2 billion from $1.3 billion. Adjusted marketing, selling and administrative expenses grew to $1.6 billion from $1.1 billion.
Key Pipeline Updates
In June, the FDA approved Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
The FDA also approved Opdivo plus Yervoy given with two cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This approval was based on results from the CheckMate -9LA study.
Moreover, the FDA approved Opdivo plus Yervoy for the first-line treatment of adult patients with metastatic NSCLC whose tumors express PD-LI>1% as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. This approval was based on data from Part 1a of the Checkmate -227 study.
In May, Zeposia was approved in Europe for the treatment of adult patients with relapsing forms of multiple sclerosis.
In June, the company and partner Acceleron Pharma Inc. XLRN obtained the European Commission’s (EC) approval for Reblozyl for the treatment of transfusion-dependent anemia in adult patients with myelodysplastic syndromes (MDS) or beta thalassemia.
Bristol Myers Squibb Company Price, Consensus and EPS Surprise
Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote
2020 Guidance Update
Bristol-Myers now projects 2020 earnings of $6.10-$6.25 per share (previous guidance: $6.00-$6.20). The company continues to expect revenues for 2020 in the range of $40.5-$42 billion (previous guidance: $40 - $42 billion). The Zacks Consensus Estimate for revenues and earnings is pegged at $41.8 billion and $6.18 per share, respectively.
The company expects returning to a stable business environment in the third quarter and minimal impact of the pandemic fourth quarter onward.
Bristol-Myers’ performance in the second quarter was encouraging. Earnings and sales beat estimates primarily on the addition of Celgene’s drugs to its portfolio. However, weak Opdivo sales are concerning. The drug faces stiff competition from Merck’s MRK Keytruda and Roche’s Tecentriq.
The acquisition of Celgene holds promise as it boosted Bristol-Myers’ oncology franchise. The increase in the earnings guidance was positive as well and should boost investor sentiment.
Bristol-Myers currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck Co., Inc. (MRK): Free Stock Analysis Report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.